nangibotide   Click here for help

GtoPdb Ligand ID: 14581

Synonyms: LR12
Immunopharmacology Ligand
Compound class: Peptide
Comment: Nangibotide (LR12) is a 12 amino-acid synthetic peptide that was designed as an inhibitor of TREM1 receptor-mediated pro-inflammatory signalling (e.g., release of IL-1β and IL-8) [7]. It is a fragment of the the soluble TREM-like transcript-1 (TLT-1) derivative LR17 [2]. Nangibotide is intended to reduce excessive inflammatory responses and reduce tissue damage. It is a useful experimental tool for further investigations into the potential of TREM1 inhibition for the treatment of acute and chronic noninfectious inflammatory disorders such as myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure.

Nangibotide was the first TREM1 inhibitor to progress as a clinical candidate.
No information available.
Summary of Clinical Use Click here for help
A phase I first-in-man drug safety and pharmacokinetics study has been completed [1].

SARS-CoV-2: Nangibotide was evaluated in patients with COVID-19-related ARDS who were assessed as having TREM1 activation [3,6].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03158948 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock Phase 2 Interventional Inotrem 4
NCT03463044 Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects Phase 1 Interventional Inotrem
NCT04429334 Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support Phase 2 Interventional Inotrem 3
NCT04055909 Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock Phase 2 Interventional Inotrem The ASTONISH study 5